Dr. Procko from the University of Illinois at Urbana-Champaign has developed a novel set of HIV-1 immunogens for use as a HIV-1 vaccine. If effective these immunogens will...
Dr. Procko from the University of Illinois at Urbana-Champaign has developed a novel set of HIV-1 immunogens for use as a HIV-1 vaccine. If effective these immunogens will allow creation of the first viable HIV-1 vaccine.
This new class of nanobubbles for the treatment of hypoxia are comprised of FDA approved compounds and provide a biocompatible environment for incorporating pharmaceutical...
This new class of nanobubbles for the treatment of hypoxia are comprised of FDA approved compounds and provide a biocompatible environment for incorporating pharmaceutical agents. Moreover, unlike traditional phospholipid or dextran nanobubbles these new nanobubbles can release their payload without the use of an external trigger such as ultrasound. Additionally, these new nanobubbles have also shown significant promise as a therapy for Central Retinal Artery Occlusion (CRAO).
Professor Beth Stadtmueller and Sonya Kumar Bharathkar have created a chimeric secretory immunoglobulin A (cSIgA) with a modified secretory component (SC) that can be used...
Professor Beth Stadtmueller and Sonya Kumar Bharathkar have created a chimeric secretory immunoglobulin A (cSIgA) with a modified secretory component (SC) that can be used in therapeutic treatment. The bispecific cSIgA can bind its target antigen and additional ligands by an engineered SC portion, such as toxins or surface antigens. This can be applied to treatment for mucosal infections such as Clostridium difficile.
As our understanding of biological systems and human diseases advance, humans are now trying to combat cancer with new development of drugs and therapeutic treatments. An...
As our understanding of biological systems and human diseases advance, humans are now trying to combat cancer with new development of drugs and therapeutic treatments. An aspect that scientists are working on is the development of personalized cancer therapies to train our immune system to recognize and target our own cancer cells. The Wang Lab has developed a new personalized cancer therapy. It is a cancer vaccine that makes cancer-cell derived exosomes more effective antigens for targeting specific tumors. This way, we can get a better chance at utilizing these particles to boost our T cells and Dendritic cells to fight against cancer.
